129
Views
1
CrossRef citations to date
0
Altmetric
Articles

Increased biologic utilization in Latino patients with psoriasis

ORCID Icon &
Pages 965-968 | Received 18 Jun 2020, Accepted 05 Jul 2020, Published online: 20 Jul 2020

References

  • Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–516.
  • Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386:983–994.
  • Kaufman BP, Alexis AF. Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in Non-White racial/ethnic groups. Am J Clin Dermatol. 2018;19:405–423.
  • Abrouk M, Lee K, Brodsky M, et al. Ethnicity affects the presenting severity of psoriasis. J Am Acad Dermatol. 2017;77:180–182.
  • Ashbaugh AG, Ekelem C, Landaverde Y, et al. Psoriatic disease in the US Latino population: a comprehensive review. Am J Clin Dermatol. 2020;21:265–274.
  • Adsit S, Zaldivar ER, Sofen H, et al. Secukinumab is efficacious and safe in Hispanic patients with moderate-to-severe plaque psoriasis: pooled analysis of four phase 3 trials. Adv Ther. 2017;34:1327–1339.
  • Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
  • Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief No. 288. 2017.
  • Yan D, Afifi L, Jeon C, et al. A cross-sectional study of psoriasis triggers among different ethno-racial groups. J Am Acad Dermatol. 2017;77:756–758.e1.
  • World Health Organization. Global report on psoriasis. Geneva: World Health Organization; 2016.
  • Sbidian E, Giboin C, Bachelez H, et al. Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort. J Eur Acad Dermatol Venereol. 2017;31:2046–2054.
  • Hendrix N, Ollendorf DA, Chapman RH, et al. Cost-effectiveness of targeted pharmacotherapy for moderate to severe plaque psoriasis. J Manag Care Spec Pharm. 2018;24:1210–1217.
  • Muddasani S, Fleischer AB Jr. United States systemic psoriasis treatments: increases in the use of biologic agents and plateau of methotrexate and oral small molecule inhibitors. J Dermatolog Treat. 2020;1–3. DOI:https://doi.org/10.1080/09546634.2020.1729951
  • Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother. 2011;12:2041–2054.
  • Feldman SR, Tian H, Wang X, Germino R. Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large U.S. claims database. J Manag Care Spec Pharm. 2018;1–11. DOI:https://doi.org/10.18553/jmcp.2018.18308
  • Control CfD. National Ambulatory Medical Care Survey. Available from: https://www.cdc.gov/nchs/ahcd/datasets_documentation_related.htm
  • Ronholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18:2297.
  • Division of Nutrition PA, and Obesity, National Center for Chronic Disease Prevention and Health Promotion. About adult BMI. Available from: https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html
  • Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–1072.
  • Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care. 2016;22:S216–S224.
  • Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377–390.
  • Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71:5–32.
  • Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149:1180–1185.
  • Gottlieb AB, Greb JE, Goldminz AM. Psoriasis trends and practice gaps. Dermatol Clin. 2016;34:235–242.
  • Menter A. Psoriasis and psoriatic arthritis treatment. Am J Manag Care. 2016;22:S225–S237.
  • Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1:CD011535.
  • Bath RK, Brar NK, Forouhar FA, et al. A review of methotrexate-associated hepatotoxicity. J Dig Dis. 2014;15:517–524.
  • Shetty A, Cho W, Alazawi W, et al. Methotrexate hepatotoxicity and the impact of nonalcoholic fatty liver disease. Am J Med Sci. 2017;354:172–181.
  • Buzney CD, Peterman C, Saraiya A, et al. Clearance of psoriasis: the impact of private versus public insurance. J Drugs Dermatol. 2015;14:119–125.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.